PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of wtpaEurope PMCEurope PMC Funders GroupSubmit a Manuscript
 
J Immunol. Author manuscript; available in PMC 2010 November 24.
Published in final edited form as:
PMCID: PMC2990881
EMSID: UKMS33142

Tyrosine Kinase 2 Controls IL-1β Production at the Translational Level

Abstract

IL-1β is an important proinflammatory cytokine with a major role in several inflammatory diseases. Expression of IL-1β is tightly regulated at the level of transcription, mRNA stability, and proteolytic processing. In this study, we report that IL-1β expression in response to LPS is also regulated at the translational level. LPS-induced IL-1β protein levels in macrophages derived from murine bone marrow are markedly increased in the absence of tyrosine kinase 2 (Tyk2). Increased IL-1β is found intra- and extracellularly, irrespective of the efficiency of IL-1β processing. We show that the absence of Tyk2 results both in higher translational rates and in enhanced association of IL-1β mRNA with polysomes. Induction and stability of IL-1β mRNA are not affected by the lack of Tyk2. We show further that the Tyk2-dependent translational inhibition is mediated by autocrine/paracrine type I IFN signaling and requires signal transducer and activator of transcription 1. Enhanced IL-1β production in Tyk2- and IFN receptor 1-deficient macrophages is also observed following Listeria monocytogenes infection. Taken together, the data describe a novel mechanism for the control of IL-1β synthesis.

Tyrosine kinase 2 (Tyk2) is a member of the Janus kinase (Jak) family of nonreceptor tyrosine kinases (1). Jaks and signal transducers and activators of transcription (Stats) constitute the Jak/Stat signal transduction cascade that is used by many cytokines and some growth factors (2). Binding of ligands to their cognate receptors induces activation of Jaks, subsequent auto- and/or transphosphorylation and phosphorylation of the signal transducing cytoplasmic receptor domains. These then serve as docking sites for Stats, which upon phosphorylation by Jaks translocate as hetero- or homodimers to the nucleus, bind to specific consensus elements in promoter regions and activate transcription of target genes. Most prominently, Tyk2 is involved in signal transduction of type I IFNs and IL-12 (3, 4). Accordingly, mice lacking Tyk2 are more sensitive to most microbial infections studied so far (3, 510). By contrast, Tyk2 deficiency results in enhanced resistance against sterile inflammation and several inflammatory diseases (6, 1115).

LPS is recognized by the TLR4 complex and leads to the activation of two main branches of signal transduction initiated at different intracellular sites. The myeloid MyD88-dependent pathway is essential for the activation of NF-κB and MAP kinases and the subsequent induction of proinflammatory cytokines, whereas the MyD88-independent pathway is required for the activation of IFN regulatory factor 3 and the expression of type I IFNs (16, 17). Type I IFNs bind to the receptor chains IFNAR1 and IFNAR2, thereby activating Tyk2, Jak1, and subsequently, mainly Stat1/Stat2 dimers. In combination with IFN regulatory factor 9 these form IFN-stimulated gene factor 3, which activates the transcription of a large number of IFN-responsive genes. Type I IFN receptor chains are widely expressed and thus autocrine/paracrine actions of type I IFNs contribute substantially to the complex biological responses to LPS treatment in most, if not all, cell types.

The central involvement of IL-1β in a wide range of inflammatory and autoimmune diseases makes it an attractive target for therapeutic interventions (1820). IL-1β expression is believed to be regulated largely at the level of transcription and by its processing and release (21, 22). In addition, regulation of IL-1β mRNA stability via AU-rich elements (ARE) has been reported (23). Pro–IL-1β synthesis is induced by LPS through activation of the NF-κB and MAPK pathways (24, 25), although NF-κB can also negatively regulate IL-1β processing (26). Pro–IL-1β can be cleaved into the biologically active cytokine by several proteases in the extracellular space but caspase (casp) 1 is the main protease responsible for cleavage within macrophages (2729). Recently, casp-8–dependent and casp-1–independent IL-1β maturation was reported in TLR2-primed, LPS-stimulated peritoneal macrophages (30). Casp-1 itself requires proteolytic processing for activation and this occurs within an activated inflammasome. LPS is a strong inducer of pro–IL-1β but a poor activator of the inflammasome and so only weakly induces the release of mature IL-1β unless a second stimulus triggers inflammasome activation (3133).

By means of a two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) approach, we recently reported that lack of Tyk2 results in strong alterations of the macrophage proteome both before and after LPS stimulation (34). In the current study, we identify IL-1β as a protein that is strongly enhanced in the absence of Tyk2 upon LPS treatment in bone marrow-derived macrophages. Mechanistically, we show that Tyk2 limits IL-1β expression at the level of translation and provide evidence that this Tyk2 function is dependent on canonical IFN-α/b signaling.

Materials and Methods

Animals and cells

Tyk2, IFNAR1, and Stat1 knockout mice have been described previously (3, 35, 36) and were backcrossed to C57BL/6 background for at least 10 generations. Bone marrow-derived macrophages were isolated and grown in the presence of CSF-1 derived from L929 cells as described previously (37). Cells were cultivated for 6 d in DMEM supplemented with 10% FCS, 15% L929 cell conditioned medium, 2 mM l-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 50 μM β-mercaptoethanol (complete medium [CM]) prior to the experiments. All cell culture reagents were from Invitrogen (Lofer, Austria). Mice were housed under specific pathogen-free conditions according to FELASA guidelines. All animal experiments were discussed and approved by the institutional ethics committee and conform with Austrian laws (68.205/0204-C/GT/2007 and 68.205/0233-II/10b/2009).

Reagents and preparation of whole cell lysates

Cells were treated with 100 ng/ml LPS (Escherichia coli serotype 055:B5, Sigma-Aldrich, St. Louis, MO) for the times indicated. IFN-β (Calbiochem, San Diego, CA) was used at the concentration of 100 U/ml. Actinomycin D (actD; Sigma-Aldrich) and cycloheximide (CHX; Sigma-Aldrich) were used at a concentration of 10 μg/ml. Whole cell lysates were prepared as described previously (34). Listeria monocytogenes (EGD strain) was kindly provided by Thomas Decker (Max F. Perutz Laboratories, University of Vienna, Vienna, Austria) and infections were performed as described (38).

2D-DIGE and protein identification by mass spectrometry

DIGE labeling, 2-DE separation, evaluation/statistical analyses and protein identification by MALDI-mass spectrometry (MS) and MS/MS have been described previously (34). See Table I for detailed MS data.

Table I
Detailed MS data for the unambiguous identification of IL-1β (Swissprot accession no. P10749)

Western blot analysis

Western blots were performed as described previously (34). The following Abs were used: goat anti–IL-1β (R&D Systems, Minneapolis, MN), mouse anti-panERK (BD Biosciences, San Diego, CA), donkey anti-goat IgG-HRP (Santa Cruz Biotechnology, Santa Cruz, CA), sheep anti-mouse IgG-HRP F(ab)’2 fragment (GE Healthcare, Munich, Germany). Quantifications were performed using ImageJ software for Mac OS X (open source, http://rsb.info.nih.gov/ij/index.html).

ATP treatment

Cells (2 × 106) were stimulated with LPS in 1.5 ml CM (see above) for 4 h, washed once with PBS, 1.5 ml DMEM containing 3 mM, 5 mM ATP (Sigma-Aldrich), or without supplements were added and cells were further incubated for 30 min.

ELISA

Cell culture supernatants were collected and centrifuged at 14,000 × g for 3 min and concentrations of IL-1β and TNF-α were determined using ELISA (R&D Systems). Detection limits of ELISAs are 10 pg/ml and 25 pg/ml for IL-1β and TNF-α, respectively.

TCA precipitation of supernatants

Supernatants (900 μl) were mixed with 13.5 μl 10% (w/v) sodium deoxy-cholate monohydrate (Sigma-Aldrich) (final concentration 0.15%) and 300 μl ice-cold 6.1 M TCA solution was added. Extracts were incubated 1 h on ice to allow protein precipitation. Samples were centrifuged at 10,000 × g for 10 min at 4°C. Supernatants were discarded, pellets were washed three times with 1 ml ice-cold acetone and dissolved in 10 μl 0.2 M NaOH, diluted in 15 μl H2O and mixed with 25 μl 2 × SDS-PAGE Laemmli sample buffer, followed by boiling for 5 min. For Western blotting, 15 μl sample was separated on a 15%T SDS-PAGE and probed with anti–IL-1β Abs.

Pulse/chase experiments and immunoprecipitation

Cells (3 × 106) were stimulated with LPS in CM (see above) for 2.5 h, then washed once with PBS and incubated in LPS containing starving medium (DMEM methionine/cysteine-free, 1% BSA, 2 mM l-glutamine, 15% conditioned medium, 100 U/ml penicillin, 100 μg/ml streptomycin) for 30 min. Medium was replaced by 1.5–2 ml pulse medium (starving medium supplemented with 70–100 μCi/ml [35S]methionine/cysteine [Met-35S-label], Hartmann Analytic, Braunschweig, Germany) and cells were incubated in the presence of LPS for the indicated pulse times. Cells were washed once with PBS and incubated in chase medium (CM supplemented with 15 mg/ml l-methionine and l-cysteine [Sigma-Aldrich]). IL-1β was immunoprecipitated from 400 μg protein with hamster anti–IL-1β Ab (BD Biosciences) using protein A-coupled Sepharose beads. Quantification of signal intensities was performed with ImageJ software as described for Western blots.

Polysome gradients

Sucrose gradient fractionation was performed as previously described (39) with minor modifications. Cells (1.5 × 107) were lysed in 1 ml ice-cold buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 1.5 mM MgCl2, 0.5% [v/v] NP-40, 500 U RiboLock) and nuclei removed by centrifugation at 3,000 × g, 4°C for 2 min. The supernatant was supplemented with 20 mM DTT, 150 μg/ml CHX, and 1 mM PMSF and centrifuged at 15,000 × g, 4°C for 5 min. Supernatants were layered onto 10 ml continuous 15–40% (w/v) sucrose gradients (containing 10 mM Tris-HCl pH 7.5, 140 mM NaCl, 1.5 mM MgCl2, 10 mM DTT, and 100 μg/ml CHX) and centrifuged at 38,000 rpm, 4°C for 2 h (Sorvall SW41 rotor; ThermoFisher Scientific, Waltham, MA). Fractions (0.5 ml) were collected manually from top to bottom. Proteins were digested with 100 μg proteinase K in the presence of 1% (w/v) SDS and 10 mM EDTA pH 8. RNA was extracted with 25:24:1 phenol-chloroform-isoamyl alcohol (Invitrogen), supplemented with 1 μl glycogen (Sigma-Aldrich, ~20 mg/ml), 225 mM sodium acetate pH 5.2, and precipitated overnight with ethanol.

Reverse transcription-quantitative PCR

Reverse transcription-quantitative PCR (RT-qPCR) of total RNA was performed as described previously (34). RT-qPCR of sucrose gradient-fractionated mRNA: two fractions each were pooled and 4 μl RNA was used for cDNA synthesis with iScript (Bio-Rad Laboratories, Vienna, Austria). RT-qPCR was performed in duplicate on Eppendorf realplex4 (Eppendorf, Vienna, Austria). Expression levels of the target genes (TNF-α, IL-1β, PAI2, NF-κB inhibitor α (NFκBia), and TATA box binding protein [TBP]) were determined by RT-qPCR in each pooled fraction and are given as percentages of the target mRNA in all fractions.

Primers and probes: the primers and probes for TNF-α (12), Ube2d2 (7), and PAI2 (34) have been described previously. IL-1β was detected with a TaqMan gene expression assay (assay ID Mm00434228_m1; Applied Biosystems). TBP and NFκBia were detected with EVAGreen (Biotium, Hayward, CA) using the following primers (5′–3′): TBP-fwd: 5′-GAATATAATCCCAAGCGATTTGC-3′ (Tm = 58°C); TBP-rev: 5′-CTGGATTGTTCTTCACTCTTGGCT-3′ (Tm = 60°C), amplicon length: 122 bp; NFκBia-fwd: 5′-TGGCCAGTGTAGCAGTCTTGAC-3′ (Tm = 60°C); and NFκBia-rev: 5′-CAGGTAGCCGTGAGTAGAGGCTAG-3′ (Tm = 59°C), amplicon length: 117 bp.

Statistical analysis of RT-qPCR and ELISA data

RT-qPCR gene expression data were investigated for differences among genotypes and time after challenge. Univariate regression was calculated with the log of the transformed target to endogenous control gene expression ratio as dependent variable. Linear contrasts were encoded such that for each time point, Tyk2–/– were compared with wild-type (WT) cells. Differences among experiments were taken into account. Analysis of ELISA data with multiple measurements was performed using the log of the data and as above. Data were analyzed with SPSS 17.0 for Mac OS-X. For the analysis of ELISA data of single treatments/time points t tests (Mann-Whitney) were used (Prism 5 software for Mac OS X; GraphPad Software, La Jolla, CA).

In vivo LPS challenge

Age- (8–10 wk) and sex-matched mice were injected i.p. with 1 mg/20 g body weight LPS. After 4 h, mice were anesthesized with ketaminexylazine and blood was collected retrobulbarly. For peritoneal lavages, mice were sacrificed and peritonea flushed with 5 ml PBS.

Results

Intracellular pro–IL-1β in response to LPS treatment is increased in the absence of Tyk2 in bone marrow-derived macrophages

Using a 2D-DIGE and MALDI-MS approach, we recently reported a regulatory role for Tyk2 in the expression of a number of proteins before and after LPS treatment, whereby 21 of them were unambiguously identified (34). In a subsequent analysis, we identified IL-1β in a spot that was differentially expressed between WT and Tyk2–/– macrophages after LPS treatment (see Materials and Methods and Table I for details on MS). IL-1β was found in whole cell lysates in a spot with a Mr of ~30 kDa and an iso-electric point around 4.6. The peptides identified were common to both mature (Mr of 17 kDa) and immature (Mr of 31 kDa) IL-1β but based on the Mr the spot could be assigned to the latter (pro–IL-1β). After 18 h, LPS treatment the levels of pro–IL-1β were found to be higher in Tyk2–/– cells than in WT cells (Fig. 1A, 1B). Spot volume ratios as determined by 2D-DIGE increased in WT cells upon 18 h LPS treatment by ~3-fold, whereas a significantly stronger increase (~14-fold) was found in the absence of Tyk2 (Fig. 1B). Enhanced levels of pro–IL-1β in whole cell lysates from Tyk2–/– macrophages were confirmed by Western blot time course experiments (Fig. 1C) and were detected from around 2 h after LPS stimulation onward. As reported previously (4042), mature IL-1β was hardly detectable in cell extracts after LPS treatment (Fig. 1C).

FIGURE 1
Pro–IL-1β protein expression is elevated in the absence of Tyk2. Macrophages were treated with LPS for the indicated times and whole cell lysates were subjected to 2D-DIGE (A, B) or Western blot analysis (C). A, Selected regions from Cy3 ...

IL-1β mRNA induction and stability are similar in WT and Tyk2–/– macrophages

Induction of IL-1β gene expression in response to LPS treatment in macrophages occurs via the MyD88-dependent pathway (43, 44), which is not believed to depend on Tyk2 (12, 34). Consistent with this notion, we found no significant differences in IL-1β mRNA levels between WT and Tyk2–/– macrophages in time-course experiments (Fig. 2A). IL-1β mRNA was induced rapidly within the first hour of LPS treatment in WT and Tyk2–/– cells, reached its maximal level expression around 12 h after LPS treatment and remained high for up to 20 h. As expected, TNF-α mRNA was induced to a similar extent in WT and Tyk2–/– macrophages (Fig. 2B). To determine also the effects of Tyk2 on mRNA stability, cells were treated with LPS for 4 h and subsequently incubated with the transcriptional inhibitor act D for the times indicated. mRNA levels of IL-1β and proinflammatory response genes as controls were determined at different times after treatment using RT-qPCR. IL-1β mRNA was stable (Fig. 2C) as described previously in the context of LPS responses (45) and no difference was observed between WT and Tyk2–/– cells. Consistent with other reports (45), mRNA of TNF-α and NFκBia decayed rapidly. No differences between WT and Tyk2–/– cells were observed for TNF-α and NFκBia mRNA decay (Fig. 2D, 2E). Ubiquitin-conjugating enzyme E2 D2 (Ube2d2) mRNA, which was used as a endogenous control for most of the RT-qPCR analyses, was very stable and as expected its level was not affected by the absence of Tyk2 (Fig. 2F).

FIGURE 2
IL-1β mRNA expression and stability is unaltered in Tyk2–/– cells. Macrophages were treated with LPS for the times indicated and total RNA was subjected to RT-qPCR for IL-1β (A) or TNF-α (B). mRNA expression levels ...

Intra- and extracellular levels of IL-1β are enhanced in the absence of Tyk2

IL-1β processing and release is tightly regulated. LPS stimulation alone massively induces pro–IL-1β production but processing and externalization occurs very inefficiently (31, 32, 46). Thus, IL-1β remains largely intracellular as unprocessed pro–IL-1β and only low levels of mature IL-1β can be detected in the extracellular space. Nevertheless, and to test whether the increased intracellular pro–IL-1β level in Tyk2–/– cells is caused by reduced IL-1β processing and/or release, we determined the amount of extracellular IL-1β with ELISA. As shown in Fig. 3A, the amounts of IL-1β protein detected in the supernatants were low in WT cells with around 50–100 pg/ml at 24 h after LPS stimulation. The level of IL-1β was increased by ~4- to 5-fold in Tyk2–/– macrophage supernatants. Again consistent with previous studies (12), secreted levels of TNF-α were similar in WT and Tyk2–/– cells (Fig. 3B).

FIGURE 3
Extracellular protein levels of IL-1β are elevated in Tyk2–/– cells. Macrophages were treated with LPS for the times indicated and cell culture supernatants collected. Extracellular protein concentrations of IL-1β (A) and ...

We next asked whether increased IL-1β production in Tyk2–/– cells is also observed under conditions that promote maturation of IL-1β (32). Macrophages were treated for 4 h with LPS, followed by 30 min stimulation with the receptor agonist ATP (3 or 5 mM). In contrast to the 8 h time point (Fig. 3A), treatment with LPS alone for 4 h resulted in barely detectable levels of IL-1β and a slight, but not significant increase in Tyk2–/– cells (Fig. 4A). As expected, extracellular levels of IL-1β in WT cells were dramatically higher (~1600 pg/ml) after addition of ATP (Fig. 4A). Importantly, significantly enhanced IL-1β levels were detected in Tyk2–/– macrophages in the presence of 3 mM and 5 mM ATP (Fig. 4A).

FIGURE 4
Pro- and mature IL-1β, and intra- and extracellular protein levels of IL-1β are higher in the absence of Tyk2, independent of the presence of ATP. Macrophages were treated with LPS for 4 h with or without subsequent addition of ATP at ...

As the ELISA might also detect unprocessed IL-1β, we used Western blot analysis to verify these results. Under our experimental conditions, IL-1β was not detectable in supernatants of cells treated with LPS alone (data not shown), whereas pro–IL-1β and mature IL-1β could be detected in supernatants of WT cells after treatment with 5 mM ATP (Fig. 4B). Strongly enhanced IL-1β levels were detected in the absence of Tyk2 and mature IL-1β was readily detectable at concentrations of 3 mM and 5 mM ATP, respectively. Importantly, mature 17 kDa IL-1β was also increased in supernatants of Tyk2-deficient cells (Fig. 4B). Intracellular, mature IL-1β was not detectable in WT cells treated with LPS/ATP (Fig. 4C). In contrast, mature IL-1β was detectable even intracellularly in Tyk2–/– cells after treatment with LPS and 5 mM ATP (Fig. 4C).

In summary, the data show that both intra- and extracellular levels of pro–IL-1β and mature IL-1β are increased in the absence of Tyk2 as compared with WT cells, independently of the presence of a trigger that promotes IL-1β processing.

Limitation of IL-1β expression depends on the presence of IFNAR1 and Stat1

In the context of macrophage LPS responses, Tyk2 is mainly associated with IFN-α/β signaling. Maximum levels of basal and/or induced expression of at least some genes that depend on functional IFN-α/β responses are only observed in the presence of Tyk2 (3, 7, 12). We thus asked whether the inhibitory role of Tyk2 in IL-1β expression may be extended to other signaling molecules of the type I IFN pathway. To this end, cells lacking IFNAR1 or Stat1 were treated with LPS for 4 or 18 h, with or without additional incubation with ATP. IL-1β expression was analyzed in supernatants by Western blotting (Fig. 5A). IL-1β levels were enhanced to a similar extent in IFNAR1–/–, Tyk2–/–, and Stat1–/– cells at both times of treatment and, additionally, levels of processed IL-1β were also clearly higher than in WT cells. Similarly, enhanced pro–IL-1β and low levels of mature IL-1β were observed intracellularly in the absence of IFNAR1, Tyk2, or Stat1 after LPS treatment, independent of the presence of ATP (Fig. 5B). We note that our data on Stat1–/– cells contradict a previous report showing reduced extracellular levels of IL-1β protein upon LPS treatment in the absence of Stat1 in thioglycollate-elicited peritoneal macrophages (47). It seems likely that this discrepancy can be explained by differences in the macrophage populations used, namely, resting versus inflammatory.

FIGURE 5
Effect of IFNAR1 and Stat1 deficiency on IL-1β production induced by LPS and Listeria monocytogenes infection. A and B, Macrophages were treated with LPS for the times indicated with or without subsequent addition of ATP for 30 min. C ...

To test whether similar effects occur in response to infection with a pathogen that readily activates the inflammasome (48), we infected macrophages with Listeria monocytogenes and monitored IL-β levels. IL-1β concentrations in supernatants of infected cells were in the range of those found in LPS/ATP-treated cells. Again, increased IL-1β was found in whole cell extracts (Fig. 5C) and cell supernatants (Fig. 5D) in the absence of either Tyk2 or IFNAR1. IL-1β secretion occurred more efficiently in cells infected with L. monocytogenes than after LPS/ATP treatment, as we could not detect any mature IL-1β in whole cell extracts (data not shown). Extracellular IL-1β amounts as detected by ELISA were increased around 5- to 10-fold in both Tyk2- and IFNAR1-deficient as compared with WT cells (Fig. 5D). In contrast, the level of TNF-α was similar in WT and Tyk2–/– macrophages and interestingly decreased in IFNAR1-deficient cells (Fig. 5E).

Based on the conclusion that LPS-induced, autocrine/paracrine IFN-α/β signaling can inhibit IL-1β protein expression, we tested whether addition of exogenous IFN-β can decrease IL-1β production. For that purpose, WT and Tyk2–/– cells were pretreated with IFN-β for 1 h, or left untreated, and then subsequently treated with LPS for 24 h, or left untreated. A clear decrease in IL-1β protein expression could be observed in WT and Tyk2–/– cells that were pre- or cotreated with IFN-β, whereby pretreatment had a more pronounced effect (Fig. 6A, data not shown). These data confirm previous observations in human whole blood cells (49) where type I IFN treatment was found to decrease IL-1β protein production. IFN-β pretreatment decreased intracellular pro–IL-1β levels by ~10-fold in WT cells as determined by quantification of Western blot data (Fig. 6B). As expected, and in accordance with the amplifying role of Tyk2 in IFN-α/β signaling (3, 4), inhibition by IFN-β still occurred but was less pronounced (~2-fold) in Tyk2–/– cells (Fig. 6B). IL-1β levels in supernatants from WT cells were decreased to below the detection limit of the ELISA (Fig. 6C) and by around 5-fold in Tyk2–/– cells. In WT and Tyk2–/– cells we were unable to observe any effect on TNF-α levels of pretreatment with IFN-β for 1 h (Fig. 6D).

FIGURE 6
Effect of exogenous IFN-β on IL-1β protein levels. Macrophages were pretreated with IFN-β for 1 h or left untreated and subsequently treated with LPS or left untreated for 24 h. A, 5 μg protein from whole cell lysates per ...

The increased amount of IL-1β in Tyk2–/– cells is caused by enhanced protein synthesis

We next determined whether IL-1β protein stability is influenced by the absence of Tyk2. Macrophages were stimulated with LPS for 4 h, the translational inhibitor CHX was added and IL-1β protein expression monitored over time. As described previously, IL-1β protein levels were increased in Tyk2–/– as compared with WT cells at 4 h of LPS stimulation. IL-1β protein levels declined after 6 h and 12 h addition of CHX in both WT and Tyk2–/– cells (Fig. 7A) and no significant differences could be observed.

FIGURE 7
Pro–IL-1β protein stability and synthesis in the presence or absence of Tyk2. A, Macrophages were treated with LPS for 4 h, 10 μg/ml CHX was added and cells were further cultivated for the times indicated. Five microgram protein ...

Because the protein synthesis inhibitor CHX might introduce artifacts, for example, by blocking the expression of a labile protease, we confirmed the results by metabolic labeling with [35S]methionine/cysteine in pulse-chase experiments. Cells were treated with LPS for 4 h, labeled with [35S]methionine/cysteine (pulse), washed and further incubated in the presence of excess cold methionine/cysteine for various times (chase). We found clear differences in IL-1β synthesis between WT and Tyk2–/– cells during the 1 h and 2 h pulse periods (Fig. 7B, 7C). The observed half-life of IL-1β in WT cells was similar to that previously described (50) and not greatly different between WT and Tyk2-deficient cells (Fig. 7B, 7D). The data thus indicate that Tyk2 deficiency results in enhanced translation of IL-1β rather than in increased protein stability.

Association of IL-1β mRNA with polysomes is enhanced in the absence of Tyk2

To test directly whether Tyk2 influences the translation of IL-1β mRNA, we fractionated cytoplasmic RNA from LPS-treated WT and Tyk2–/– macrophages via sucrose gradients (Fig. 8A) and compared mRNA distributions among the different fractions (Fig. 8BE). After 4 h LPS stimulation of WT cells, IL-1β mRNA was found in the ribosome-free fractions as well as in association with polysomes (Fig. 8B). In contrast, IL-1β mRNA was significantly enriched in the polysomal fractions in Tyk2–/– cells (p = 0.019). We also observed differences in the IL-1β polysome profiles after 14 h of LPS treatment, although IL-1β mRNAs were generally shifted toward the ribosome-free mRNA fractions (data not shown). As previously reported (51, 52), TNF-α mRNA was found in monosomal and polysomal fractions in WT cells treated with LPS (Fig. 8C). In accordance with the unchanged expression of TNF-α protein, TNF-α mRNA showed similar polysome profiles in WT and Tyk2-deficient cells (Fig. 8C). Furthermore, we observed no difference in mRNA profiles of the two housekeeping genes, TBP and Ube2d2 (Fig. 8D, data not shown). To assess the specificity of the translational effects, we monitored plasminogen activator inhibitor 2 (PAI2/serpinb2) mRNA. We had previously identified PAI2 as an LPS-inducible protein whose expression is regulated posttranscriptionally by Tyk2-dependent mechanisms (34). In support of and extending these results, we show that significantly more PAI2 mRNA associates with polysomes in the absence of Tyk2 (Fig. 8E, p = 0.008).

FIGURE 8
Polysome profile of IL-1β, TNF-α, TBP, and PAI2 mRNAs. Macrophages were treated with LPS for 4 h and cytoplasmic extracts separated in a continuous 15–40% sucrose gradient by ultracentrifugation. Fractions were manually collected ...

Local IL-1β levels are increased in the absence of Tyk2 after LPS challenge in vivo

Previous studies have not reported differences in the in vivo IL-1β levels in Tyk2-deficient mice treated with LPS (12). Because this analysis was limited to systemic cytokine levels and to very early time points after LPS injection, we examined in more detail whether Tyk2 might have an inhibitory role on IL-1β production in vivo. WT and Tyk2–/– mice were injected i.p. with LPS and IL-1β was measured in peritoneal lavages and in sera. As shown in Fig. 9A, IL-1β levels were increased ~2-fold in the peritonea of Tyk2–/– as compared with WT mice at 4 h post injection. Although the increase in IL-1β was less pronounced than in macrophages in vitro, the result supports our model for an inhibitory role of Tyk2 on IL-1β production. In contrast, serum levels of IL-1β were slightly lower in Tyk2–/– mice at 4 h after challenge (Fig. 9B), suggesting differences in the regulation of local versus systemic IL-1β. Alternatively, kinetic differences in the regulatory pathways might lie behind the apparent differential effect of Tyk2 deficiency on IL-1β levels in the peritoneal cavity and systemically.

FIGURE 9
Effect of Tyk2 deficiency on IL-1β production in vivo. WT and Tyk2–/– mice were injected with LPS (1 mg/20 g body weight) i.p. IL-1β was measured 4 h after challenge in (A) peritoneal lavages and (B) sera by ELISA. Mean ...

Discussion

We show that IL-1β protein expression in response to LPS is strongly increased in the absence of Tyk2 and that the effect does not stem from changes to IL-1β mRNA induction or stability (Figs. 1AC, 2A, 2C). The lack of inhibition of IL-1β mRNA induction is in accordance with previous observations that activation of the NF-κB and MAPK pathways is normal in Tyk2-deficient macrophages (12, 34). We can eliminate the possibility that defects in processing/release of IL-1β lie behind the enhanced intracellular IL-1β levels, as IL-1β was increased in cell supernatants (Fig. 3A). Under conditions that efficiently activate the inflammasome and pro–IL-1β conversion (i.e., ATP treatment), the levels of mature IL-1β in Tyk2-deficient macrophages are enhanced (Figs. 4B, 4C, 5A, 5B). Similarly, intra- and extracellular IL-1β levels were enhanced in Tyk2–/– macrophages infected with L. monocytogenes (Fig. 5C, 5D). By pulse–chase experiments and using the translational inhibitor CHX, we show that IL-1β protein stability does not depend on the presence of Tyk2 (Fig. 7A, 7B, 7D). In contrast, IL-1β protein synthesis within a given pulse-period is enhanced in Tyk2–/– cells (Fig. 7B, 7C), suggesting an increased rate of translation. In line with this finding, IL-1β mRNA association with polysomes is enhanced in the absence of Tyk2 (Fig. 8B). The association of PAI2 mRNA with polysomes also increases (Fig. 8E), providing a mechanistic explanation for the posttranscriptional upregulation of PAI2 in Tyk2–/– cells that has been reported previously (34). Importantly, TNF-α mRNA shows similar polysome profiles in WT and Tyk2–/– cells (Fig. 8C) and similar levels of TNF-α protein are found in cell supernatants (Fig. 3B). Hence, the translational inhibition mediated by Tyk2 is specific, at least to some degree.

An increase in IL-1β protein level is observed in IFNAR1–/– and Stat1–/– macrophages, both intra- and extracellularly and independent of ATP treatment (Fig. 5A, 5B). Furthermore, IFN-β pretreatment inhibits LPS-induced IL-1β protein expression in WT cells, and to a lesser extent in Tyk2–/– cells, without affecting TNF-α levels (Fig. 6). This argues that autocrine/paracrine canonical IFN-α/β signaling is the signaling cascade involved, although we have as yet no direct evidence for an effect of IFNAR1 and Stat1 on translational control of IL-1β.

IFN-mediated translational inhibition has been known for a long time (5355) and the underlying mechanisms have been extensively studied. Activated IFN-inducible RNA-dependent protein kinase phosphorylates the α subunit of eukaryotic translation initiation factor 2A, which results in the inhibition of viral protein synthesis (56, 57). Interestingly, Tyk2 has been reported to activate protein kinase R directly (58). Two other closely related and IFN-inducible proteins, ISG54 (IFIT2) and ISG56 (IFIT1), can negatively regulate translation (5962) by inhibiting the formation of the translation initiation complex, although they target different steps (63). Interestingly, the level of stimulation of both IFIT1 and IFIT3 (another member of the IFIT protein family) in response to LPS is reduced in the absence of Tyk2 (34). Little is known about the specificity of these pathways and it is difficult to explain the effects on the translation of IL-1β and PAI2 but not TNF-α and NFκBia mRNAs (Fig. 8). It is noteworthy that IL-1β and PAI2 mRNAs are both fairly stable, whereas TNF-α and NFκBia mRNAs decay more rapidly [Fig. 2CF, data not shown, and (45)]. It may be interesting to analyze whether stable mRNAs are more subject to translational regulation than unstable ones. High-throughput polysomal profiling experiments or ribosome sequencing approaches would be required to address these speculations. A recent report describes positive regulatory effects of IFNs on translation that appear to be specific to genes stimulated by IFN (64).

A large number of cytokines are known to be regulated at the posttranscriptional level (65). Regulation occurs via AREs in the 3′-UTRs of the mRNAs and several different ARE-binding proteins regulate mRNA stability positively or negatively and can also affect translational efficiency. Early studies reported that IL-1β can be regulated at the translational level under certain conditions (6668) but the mechanism and stimuli involved remain largely unknown. More recently (52), steroid receptor coactivator-3 has been shown to be required for the translational repression of TNF-α and IL-1β in response to LPS in peritoneal macrophages, although the underlying mechanism was only described for TNF-α. IFN-α/β, and p38 MAPK synergistically induce expression of the ARE-BP tristetraprolin (TTP) (69). TTP destabilizes several cytokine and chemokine mRNAs, including IL-1β (7072), and can also influence translation (73). Surprisingly, we find that TTP expression is increased in response to LPS in the absence of Tyk2 (data not shown), arguing against an involvement of TTP in the translational regulation of IL-1β. However, TTP activity is known to be regulated by phosphorylation (74) and it is possible that Tyk2 affects the phosphorylation status of TTP.

Tyk2–/– mice are highly resistant to high-dose LPS-mediated endotoxin shock, but serum levels of TNF-α and IL-1β have been reported to be normal in these mice at early stages (1.5 h) after LPS injection (12). In support of our in vitro data, we find increased IL-1β levels in the peritoneal lavages from Tyk2–/– mice after LPS injection (Fig. 9A). Interestingly, and extending previous results (12), systemic IL-1β levels are slightly but significantly lower in Tyk2–/– mice 4 h after LPS challenge (Fig. 9B). Our data thus point to differences in the regulation of local versus systemic IL-1β production. The underlying mechanisms are unclear but it is possible that IL-1β in the peritoneal cavity and the blood may stem largely from different sources and that positive/negative regulatory pathways might be differentially active at different times, in different tissues, cell types, and/or in response to activation by different stimuli. Consistent with this hypothesis, we see decreased IL-1β production in the lungs of Tyk2–/– mice after intranasal LPS administration (data not shown). We conclude that the inhibitory role of Tyk2 is relevant in vivo, although its specific contribution to the complex regulation of IL-1β is highly dependent on the cellular context and, presumably, the specific mode and state of activation.

IL-1β–deficient mice respond to systemic LPS challenge similar to WT mice (75), so it is unlikely that the enhanced local IL-1β expression in the absence of Tyk2 contributes to the LPS-resistant phenotype. Nevertheless, the suppressive role of Tyk2 on IL-1β expression that we describe raises the possibility that Tyk2 might have protective functions during IL-1β–driven diseases. In mice, IL-1β is involved in the pathogenesis of several autoimmune and inflammatory diseases, for example, turpentine-induced local inflammation, contact hypersensitivity, and collagen-induced arthritis (76). Tyk2 seems not to act protectively during autoimmune and inflammatory diseases but may actually exacerbate the symptoms. An exception is contact hypersensitivity, where Tyk2 exerts protective functions: Tyk2–/– mice show increased sensitivity (77). Enhanced IL-1β expression in the absence of Tyk2 would be consistent with these findings. However, it is important to bear in mind that other functions of Tyk2, in particular in IL-12 signaling/IFN-γ production, might override the effects of Tyk2 on IL-1β expression.

In summary, we report a hitherto undescribed negative regulatory function for Tyk2 on IL-1β expression in response to LPS. We show that this occurs at the level of translation and most probably depends on canonical type I IFN signaling.

Acknowledgments

We thank Claus Vogl for supervision of statistical analysis. We also thank Caroline Lassnig and Graham Tebb for critically reading the manuscript. We thank Thomas Kolbe for mouse breeding and coordination.

The work was supported by the Austrian Science Fund (SFB-F28 to M.M. and B.S.) and the Austrian Federal Ministry for Science and Research (GZ.200.191/1-II/1a/2008 to Biomodels Austria).

Abbreviations used in this paper

actD
actinomycin D
ARE
AU-rich elements
casp
caspase
CHX
cycloheximide
CM
complete medium
2D-DIGE
two-dimensional fluorescence difference gel electrophoresis
I
IFNAR1–/–
IFIT
IFN-induced protein with tetratripeptide repeats
Jak
Janus kinase
MOI
multiplicity of infection
MS
mass spectrometry
nd
not detectable
NFκBia
NF-κB inhibitor α
PAI2
plasminogen activator inhibitor 2
RT-qPCR
reverse transcription-quantitative PCR
S
Stat1–/–
Stat
signal transducers and activators of transcription
T
Tyk2–/–
TBP
TATA-box-binding protein
TTP
tristetraprolin
Tyk2
tyrosine kinase 2
Ube2d2
ubiquitin-conjugating enzyme E2 D2
W
WT
WT
wild-type

Footnotes

Disclosures The authors have no financial conflicts of interest.

References

1. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin. Cell Dev. Biol. 2008;19:385–393. [PubMed]
2. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 2007;282:20059–20063. [PubMed]
3. Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, McCoy B, Bogdan C, Decker T, Brem G, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity. 2000;13:549–560. [PubMed]
4. Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, Shibamori M, Yamashita M, Numata A, Takase K, Kobayashi S, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity. 2000;13:561–571. [PubMed]
5. Schleicher U, Mattner J, Blos M, Schindler H, Röllinghoff M, Karaghiosoff M, Müller M, Werner-Felmayer G, Bogdan C. Control of Leishmania major in the absence of Tyk2 kinase. Eur. J. Immunol. 2004;34:519–529. [PubMed]
6. Shaw MH, Boyartchuk V, Wong S, Karaghiosoff M, Ragimbeau J, Pellegrini S, Muller M, Dietrich WF, Yap GS. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc. Natl. Acad. Sci. USA. 2003;100:11594–11599. [PubMed]
7. Strobl B, Bubic I, Bruns U, Steinborn R, Lajko R, Kolbe T, Karaghiosoff M, Kalinke U, Jonjic S, Müller M. Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J. Immunol. 2005;175:4000–4008. [PubMed]
8. Aizu K, Li W, Yajima T, Arai T, Shimoda K, Nimura Y, Yoshikai Y. An important role of Tyk2 in APC function of dendritic cells for priming CD8+ T cells producing IFN-gamma. Eur. J. Immunol. 2006;36:3060–3070. [PubMed]
9. Yap GS, Ortmann R, Shevach E, Sher A. A heritable defect in IL-12 signaling in B10.Q/J mice. II. Effect on acute resistance to Toxoplasma gondii and rescue by IL-18 treatment. J. Immunol. 2001;166:5720–5725. [PubMed]
10. Nakamura R, Shibata K, Yamada H, Shimoda K, Nakayama K, Yoshikai Y. Tyk2-signaling plays an important role in host defense against Escherichia coli through IL-23-induced IL-17 production by gammadelta T cells. J. Immunol. 2008;181:2071–2075. [PubMed]
11. Costantino G, Egerbacher M, Kolbe T, Karaghiosoff M, Strobl B, Vogl C, Helmreich M, Müller M. Tyk2 and signal transducer and activator of transcription 1 contribute to intestinal I/R injury. Shock. 2008;29:238–244. [PubMed]
12. Karaghiosoff M, Steinborn R, Kovarik P, Kriegshäuser G, Baccarini M, Donabauer B, Reichart U, Kolbe T, Bogdan C, Leanderson T, et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol. 2003;4:471–477. [PubMed]
13. Ortmann R, Smeltz R, Yap G, Sher A, Shevach EM. A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis. J. Immunol. 2001;166:5712–5719. [PubMed]
14. Spach KM, Noubade R, McElvany B, Hickey WF, Blankenhorn EP, Teuscher C. A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis. J. Immunol. 2009;182:7776–7783. [PMC free article] [PubMed]
15. Oyamada A, Ikebe H, Itsumi M, Saiwai H, Okada S, Shimoda K, Iwakura Y, Nakayama KI, Iwamoto Y, Yoshikai Y, Yamada H. Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J. Immunol. 2009;183:7539–7546. [PubMed]
16. Kawai T, Akira S. TLR signaling. Semin. Immunol. 2007;19:24–32. [PubMed]
17. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat. Rev. Immunol. 2009;9:535–542. [PubMed]
18. Dinarello CA. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 2002;20(5, Suppl 27):S1–S13. [PubMed]
19. Dinarello CA. Blocking IL-1 in systemic inflammation. J. Exp. Med. 2005;201:1355–1359. [PMC free article] [PubMed]
20. Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev. Drug Discov. 2004;3:330–339. [PubMed]
21. Hazuda DJ, Strickler J, Kueppers F, Simon PL, Young PR. Processing of precursor interleukin 1 beta and inflammatory disease. J. Biol. Chem. 1990;265:6318–6322. [PubMed]
22. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356:768–774. [PubMed]
23. Lu JY, Sadri N, Schneider RJ. Endotoxic shock in AUF1 knockout mice mediated by failure to degrade proinflammatory cytokine mRNAs. Genes Dev. 2006;20:3174–3184. [PubMed]
24. Doyle SL, O’Neill LA. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem. Pharmacol. 2006;72:1102–1113. [PubMed]
25. Hiscott J, Marois J, Garoufalis J, D’Addario M, Roulston A, Kwan I, Pepin N, Lacoste J, Nguyen H, Bensi G, et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol. Cell. Biol. 1993;13:6231–6240. [PMC free article] [PubMed]
26. Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, Göktuna SI, Neuenhahn M, Fierer J, Paxian S, et al. NF-kappaB is a negative regulator of IL-1βeta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell. 2007;130:918–931. [PMC free article] [PubMed]
27. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J, et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell. 1995;80:401–411. [PubMed]
28. Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, Flavell RA. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science. 1995;267:2000–2003. [PubMed]
29. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007;14:10–22. [PubMed]
30. Maelfait J, Vercammen E, Janssens S, Schotte P, Haegman M, Magez S, Beyaert R. Stimulation of Toll-like receptor 3 and 4 induces interleukin-1beta maturation by caspase-8. J. Exp. Med. 2008;205:1967–1973. [PMC free article] [PubMed]
31. Dinarello CA. Unraveling the NALP-3/IL-1beta inflammasome: a big lesson from a small mutation. Immunity. 2004;20:243–244. [PubMed]
32. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 2006;176:3877–3883. [PubMed]
33. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood. 2009;113:2324–2335. [PubMed]
34. Radwan M, Miller I, Grunert T, Marchetti-Deschmann M, Vogl C, O’Donoghue N, Dunn MJ, Kolbe T, Allmaier G, Gemeiner M, et al. The impact of tyrosine kinase 2 (Tyk2) on the proteome of murine macrophages and their response to lipopolysaccharide (LPS) Proteomics. 2008;8:3469–3485. [PubMed]
35. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996;84:443–450. [PubMed]
36. Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264:1918–1921. [PubMed]
37. Baccarini M, Bistoni F, Lohmann-Matthes ML. In vitro natural cell-mediated cytotoxicity against Candida albicans: macrophage precursors as effector cells. J. Immunol. 1985;134:2658–2665. [PubMed]
38. Reutterer B, Stockinger S, Pilz A, Soulat D, Kastner R, Westermayer S, Rülicke T, Müller M, Decker T. Type I IFN are host modulators of strain-specific Listeria monocytogenes virulence. Cell. Microbiol. 2008;10:1116–1129. [PubMed]
39. Muellner EW, Garcia-Sanz JA. Manual of immunological methods. Academic Press; London: 1997. Polysome gradients.
40. Pelegrin P, Barroso-Gutierrez C, Surprenant A. P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J. Immunol. 2008;180:7147–7157. [PubMed]
41. Verhoef PA, Estacion M, Schilling W, Dubyak GR. P2X7 receptor-dependent blebbing and the activation of Rho-effector kinases, caspases, and IL-1 beta release. J. Immunol. 2003;170:5728–5738. [PubMed]
42. Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Melchiorri L, Baricordi OR, Di Virgilio F. Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J. Immunol. 1997;159:1451–1458. [PubMed]
43. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 1999;11:115–122. [PubMed]
44. Hirotani T, Yamamoto M, Kumagai Y, Uematsu S, Kawase I, Takeuchi O, Akira S. Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 domain containing adaptor inducing IFN-beta. Biochem. Biophys. Res. Commun. 2005;328:383–392. [PubMed]
45. Hao S, Baltimore D. The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat. Immunol. 2009;10:281–288. [PMC free article] [PubMed]
46. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1{beta} in monocytes and macrophages. Blood. 2008;13:2324–2335. [PubMed]
47. Joshi VD, Kalvakolanu DV, Chen W, Zhang L, Kang TJ, Thomas KE, Vogel SN, Cross AS. A role for Stat1 in the regulation of lipopolysaccharide-induced interleukin-1beta expression. J. Interferon Cytokine Res. 2006;26:739–747. [PubMed]
48. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat. Rev. Immunol. 2007;7:31–40. [PubMed]
49. Huang Y, Blatt LM, Taylor MW. Type 1 interferon as an anti-inflammatory agent: inhibition of lipopolysaccharide-induced interleukin-1 beta and induction of interleukin-1 receptor antagonist. J. Interferon Cytokine Res. 1995;15:317–321. [PubMed]
50. Moors MA, Mizel SB. Proteasome-mediated regulation of interleukin-1beta turnover and export in human monocytes. J. Leukoc. Biol. 2000;68:131–136. [PubMed]
51. Kontoyiannis D, Kotlyarov A, Carballo E, Alexopoulou L, Blackshear PJ, Gaestel M, Davis R, Flavell R, Kollias G. Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology. EMBO J. 2001;20:3760–3770. [PubMed]
52. Yu C, York B, Wang S, Feng Q, Xu J, O’Malley BW. An essential function of the SRC-3 coactivator in suppression of cytokine mRNA translation and inflammatory response. Mol. Cell. 2007;25:765–778. [PMC free article] [PubMed]
53. Kerr IM, Friedman RM, Brown RE, Ball LA, Brown JC. Inhibition of Protein Synthesis in Cell-Free Systems from Interferon-Treated, Infected Cells: Further Characterization and Effect of Formylmethionyl-tRNA (F) J. Virol. 1974;13:9–21. [PMC free article] [PubMed]
54. Metz DH, Esteban M. Interferon inhibits viral protein synthesis in L cells infected with vaccinia virus. Nature. 1972;238:385–388. [PubMed]
55. Friedman RM, Esteban RM, Metz DH, Tovell DR, Kerr IM, Williamson R. Translation of RNA by L cell extracts: Effect of interferon. FEBS Lett. 1972;24:273–277. [PubMed]
56. Sadler AJ, Williams BR. Structure and function of the protein kinase R. Curr. Top. Microbiol. Immunol. 2007;316:253–292. [PubMed]
57. Hovanessian AG. On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 2′-5′oligoadenylate synthetases and the protein kinase PKR. Cytokine Growth Factor Rev. 2007;18:351–361. [PubMed]
58. Su Q, Wang S, Baltzis D, Qu LK, Raven JF, Li S, Wong AH, Koromilas AE. Interferons induce tyrosine phosphorylation of the eIF2alpha kinase PKR through activation of Jak1 and Tyk2. EMBO Rep. 2007;8:265–270. [PubMed]
59. Guo J, Hui DJ, Merrick WC, Sen GC. A new pathway of translational regulation mediated by eukaryotic initiation factor 3. EMBO J. 2000;19:6891–6899. [PubMed]
60. Terenzi F, Pal S, Sen GC. Induction and mode of action of the viral stress-inducible murine proteins, P56 and P54. Virology. 2005;340:116–124. [PubMed]
61. Hui DJ, Terenzi F, Merrick WC, Sen GC. Mouse p56 blocks a distinct function of eukaryotic initiation factor 3 in translation initiation. J. Biol. Chem. 2005;280:3433–3440. [PubMed]
62. Hui DJ, Bhasker CR, Merrick WC, Sen GC. Viral stress-inducible protein p56 inhibits translation by blocking the interaction of eIF3 with the ternary complex eIF2.GTP.Met-tRNAi. J. Biol. Chem. 2003;278:39477–39482. [PubMed]
63. Terenzi F, Saikia P, Sen GC. Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO J. 2008;27:3311–3321. [PubMed]
64. Kaur S, Sassano A, Dolniak B, Joshi S, Majchrzak-Kita B, Baker DP, Hay N, Fish EN, Platanias LC. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc. Natl. Acad. Sci. USA. 2008;105:4808–4813. [PubMed]
65. Anderson P. Post-transcriptional control of cytokine production. Nat. Immunol. 2008;9:353–359. [PubMed]
66. Kaspar RL, Gehrke L. Peripheral blood mononuclear cells stimulated with C5a or lipopolysaccharide to synthesize equivalent levels of IL-1 beta mRNA show unequal IL-1 beta protein accumulation but similar polyribosome profiles. J. Immunol. 1994;153:277–286. [PubMed]
67. Schindler R, Clark BD, Dinarello CA. Dissociation between interleukin-1 beta mRNA and protein synthesis in human peripheral blood mononuclear cells. J. Biol. Chem. 1990;265:10232–10237. [PubMed]
68. Herzyk DJ, Allen JN, Marsh CB, Wewers MD. Macrophage and monocyte IL-1 beta regulation differs at multiple sites. Messenger RNA expression, translation, and post-translational processing. J. Immunol. 1992;149:3052–3058. [PubMed]
69. Sauer I, Schaljo B, Vogl C, Gattermeier I, Kolbe T, Müller M, Blackshear PJ, Kovarik P. Interferons limit inflammatory responses by induction of tristetraprolin. Blood. 2006;107:4790–4797. [PubMed]
70. Blackshear PJ. Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochem. Soc. Trans. 2002;30:945–952. [PubMed]
71. Carrick DM, Lai WS, Blackshear PJ. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res. Ther. 2004;6:248–264. [PMC free article] [PubMed]
72. Schaljo B, Kratochvill F, Gratz N, Sadzak I, Sauer I, Hammer M, Vogl C, Strobl B, Müller M, Blackshear PJ, et al. Tristetraprolin is required for full anti-inflammatory response of murine macrophages to IL-10. J. Immunol. 2009;183:1197–1206. [PMC free article] [PubMed]
73. Grosset C, Boniface R, Duchez P, Solanilla A, Cosson B, Ripoche J. In vivo studies of translational repression mediated by the granulocyte-macrophage colony-stimulating factor AU-rich element. J. Biol. Chem. 2004;279:13354–13362. [PubMed]
74. Sandler H, Stoecklin G. Control of mRNA decay by phosphorylation of tristetraprolin. Biochem. Soc. Trans. 2008;36:491–496. [PubMed]
75. Fantuzzi G, Zheng H, Faggioni R, Benigni F, Ghezzi P, Sipe JD, Shaw AR, Dinarello CA. Effect of endotoxin in IL-1 beta-deficient mice. J. Immunol. 1996;157:291–296. [PubMed]
76. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009;27:519–550. [PubMed]
77. Hosogi M, Tonogaito H, Aioi A, Hamada K, Shimoda K, Muromoto R, Matsuda T, Miyachi Y. Hapten-induced contact hypersensitivity is enhanced in Tyk2-deficient mice. J. Dermatol. Sci. 2004;36:51–56. [PubMed]